| Citation: |
DOU Qiaohua, GUO Xiaofang, ZHU Xiaofei, ZHANG Yueyue, YANG Fan. Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2019, 46(9): 766-772. DOI: 10.3971/j.issn.1000-8578.2019.19.0150
|
To evaluate the antitumor efficacy of lapatinib in combination with cisplatin on esophageal squamous cell carcinoma (ESCC) and related mechanisms.
Combined effects of lapatinib and cisplatin on the proliferation of ESCC cells were measured by MTT assay, and the combination index values were calculated by Chou-Talalay method. PI staining assay and Annexin V-FITC/PI staining assay were used to analyze the cell cycle arrest and cell apoptosis after the treatment with lapatinib, cisplatin and lapatinib plus cisplatin. The activation of EGFR and HER2 as well as downstream signaling molecules were detected by Western blot.
The combination of lapatinib and cisplatin showed synergistic inhibitory effect on the proliferation of ESCC cells with the combination index (CI) values less than 1. Lapatinib in combination with cisplatin blocked cell cycle at G2/M phase, and induced significantly the apoptosis of ESCC cells. The underlying mechanisms of potentiated effects of combined treatment were associated with reduced phosphorylation of EGFR and HER2 and the downstream signaling molecules AKT and ERK.
The combination of lapatinib and cisplatin play synergistic antitumor effects on ESCC in vitro, suggesting that their combination is one of the promising treatment strategies for ESCC patients with EGFR and HER2 overexpression.
| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
|
| [2] |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1): 1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01
|
| [3] |
Wang VE, Grandis JR, Ko AH. New strategies in esophageal carcinoma: translational insights from signaling pathway and immune checkpoints[J]. Clin Cancer Res, 2016, 22(17): 4283-4290. doi: 10.1158/1078-0432.CCR-16-0292
|
| [4] |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial[J]. Lancet, 2010, 376(9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X
|
| [5] |
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39. doi: 10.1016/S0140-6736(13)61719-5
|
| [6] |
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235. doi: 10.1016/S1470-2045(14)70420-6
|
| [7] |
Jia J, Cui Y, Lu M, et al. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma[J]. Clin Transl Oncol, 2016, 18(6): 592-598. doi: 10.1007/s12094-015-1406-8
|
| [8] |
Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J]. Gastric Cancer, 2015, 18(3): 476-484. doi: 10.1007/s10120-014-0402-y
|
| [9] |
Gerson JN, Skariah S, Denlinger CS, et al. Perspectives of HER2-targeting in gastric and esophageal cancer[J]. Expert Opin Investig Drugs, 2017, 26(5): 531-540. doi: 10.1080/13543784.2017.1315406
|
| [10] |
Kawaguchi Y, Kona K, Mimura K, et al. Targeting EGFR and HER-2 with Cetuximab- and trastuzumab-mediated immunotherapy in esophageal squamous cell carcinoma[J]. Br J Cancer, 2007, 97(4): 494-501. doi: 10.1038/sj.bjc.6603885
|
| [11] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-posivite advanced breast cancer[J]. N Engl J Med, 2006, 355(26): 2733-2743. doi: 10.1056/NEJMoa064320
|
| [12] |
王士群, 朱宇珍, 郑学宝. Chou-Talalay在抗肿瘤联合用药中的研究应用概况[J].中国现代应用药学, 2013, 30(4): 449-453. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgxdyyyx201304029
Wang SQ, Zhu YZ, Zheng XB. Study and application of Chou-Talalay method for anti-tumor drug combination[J]. Zhongguo Xian Dai Ying Yong Yao Xue, 2013, 30(4): 449-453. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgxdyyyx201304029
|
| [13] |
Guo XF, Zhu XF, Zhong GS, et al. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma[J]. Oncol Rep, 2012, 27(5): 1639-1645. http://europepmc.org/abstract/MED/22293713
|
| [14] |
Fichter CD, Timme S, Braun JA, et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer[J]. Int J Cancer, 2014, 135(7): 1517-1530. doi: 10.1002/ijc.28771
|
| [15] |
Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial[J]. JAMA Oncol, 2017, 3(11): 1520-1528. doi: 10.1001/jamaoncol.2017.1598
|
| [16] |
Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial[J]. Lancet Oncol, 2014, 15(8): 894-904. doi: 10.1016/S1470-2045(14)70024-5
|
| [17] |
Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus[J]. Cancer, 2011, 117(7): 1409-1414. doi: 10.1002/cncr.25602
|
| [18] |
Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB-2 amplified locally advanced or metastatic breast cancer[J]. J Clin Oncol, 2008, 26(18): 2999-3005. doi: 10.1200/JCO.2007.14.0590
|
| [19] |
Powles T, Huddart RA, Elliott T, et al. Phase Ⅲ, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor1/2-positive metastatic bladder cancer[J]. J Clin Oncol, 2017, 35(1): 48-55. doi: 10.1200/JCO.2015.66.3468
|
| [20] |
Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomized phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Oncologie[J]. Eur J Cancer, 2015, 51(5): 569-576. doi: 10.1016/j.ejca.2015.01.059
|
| [21] |
Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1183-1192. doi: 10.1016/S1470-2045(13)70411-X
|
| [22] |
Thallinger C, Lang I, Kuhar CG, et al. Phase Ⅱ study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial[J]. BMC Cancer, 2016, 16: 121. doi: 10.1186/s12885-016-2171-y
|
| [23] |
Coley HM, Shotton CF, Ajose-Adeogun A, et al. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents[J]. Biochem Pharmacol, 2006, 72(8): 941-948. doi: 10.1016/j.bcp.2006.07.022
|
| [24] |
Kondo N, Tsukuda M, Ishiguro Y, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma[J]. Oncol Rep, 2010, 23(4): 957-963. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_ddc1c60f672d2b1dbfd9f42255d1bae2
|
| [25] |
MuHugh LA, Sayan AE, Mejlvang J, et al. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells[J]. Int J Oncol, 2009, 34(4): 1155-1163. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=22f003b41b4384c83c9570da48b2302d
|
| [26] |
Saito S, Morishima K, Ui T, et al. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma[J]. BMC Cancer, 2015, 15: 82. doi: 10.1186/s12885-015-1065-8
|
| [27] |
Hou W, Qin X, Zhu X, et al. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models[J]. Oncol Rep, 2013, 30(2): 707-714. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=07ca0c99f833b05c1c6ac96abba7c282
|
| [28] |
Rusnak DW, Alligood KJ, Mullin RJ, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumor cell lines[J]. Cell Prolif, 2007, 40(4): 580-594. doi: 10.1111/j.1365-2184.2007.00455.x
|
| [29] |
Li XQ, Ouyang ZG, Zhang SH, et al. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin[J]. Cancer Biol Ther, 2014, 15(4): 398-408. doi: 10.4161/cbt.27626
|
| [30] |
Van Schaeybroeck S, Kyula J, Kelly DM, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells[J]. Mol Cancer Ther, 2006, 5(5): 1154-1165. doi: 10.1158/1535-7163.MCT-05-0446
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: